Caroline Stout
Chief Investment Officer bei PANACEA ACQUISITION CORP. II
Profil
Caroline C.
Stout is currently the Director at Neogene Therapeutics, Inc., Independent Director at Affinia Therapeutics, Inc., Partner at EcoR1 Capital, LLC, and Chief Investment Officer at Panacea Acquisition Corp.
II.
Previously, she served as the Chief Investment Officer at Panacea Acquisition Corp.
Ms. Stout completed her undergraduate degree at Georgetown University in 2013.
Aktive Positionen von Caroline Stout
Unternehmen | Position | Beginn |
---|---|---|
PANACEA ACQUISITION CORP. II | Chief Investment Officer | 01.01.2021 |
EcoR1 Capital, LLC
EcoR1 Capital, LLC Investment ManagersFinance EcoR1 Capital LLC (EcoR1) is an independent registered investment advisor and hedge fund manager headquartered in San Francisco, California. The firm was founded by Oleg Nodelman in 2012. EcoR1 serves as the general partner of and investment adviser to investment funds and provides investment advice to separate account clients. | Analyst-Equity | 01.01.2014 |
Neogene Therapeutics, Inc.
Neogene Therapeutics, Inc. BiotechnologyHealth Technology Neogene Therapeutics, Inc. engages in the provision T cell therapies to treat cancer. The company was founded by Ton N. M. Schumacher and Carsten Linnemann and is headquartered in New York, NY. | Direktor/Vorstandsmitglied | 06.10.2020 |
Affinia Therapeutics, Inc.
Affinia Therapeutics, Inc. BiotechnologyHealth Technology Affinia Therapeutics, Inc. is a preclinical stage company, which engages in the research and development of gene therapy. It offers Affinia Rationally-designed Therapies (ART) platform, which develops novel therapies, focusing on the key components of a gene therapy: capsids, which are the outer shells of a virus used to package the genetic code to treat a disease; promoters, which control how the cells read the genetic code that is delivered; and manufacturing approaches, which determine the quality and cost of potential medicines. The company was founded by Luk Vandenberghe, Botond Roska, and Aaron Tward in 2019 and is headquartered in Waltham, MA. | Direktor/Vorstandsmitglied | 01.04.2021 |
Ehemalige bekannte Positionen von Caroline Stout
Unternehmen | Position | Ende |
---|---|---|
Panacea Acquisition Corp.
Panacea Acquisition Corp. Financial ConglomeratesFinance Panacea Acquisition Corp. is a blank check company with the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. The company was founded in April 2020 and is headquartered in San Francisco, CA. | Chief Investment Officer | - |
Ausbildung von Caroline Stout
Georgetown University | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
Private Unternehmen | 5 |
---|---|
EcoR1 Capital, LLC
EcoR1 Capital, LLC Investment ManagersFinance EcoR1 Capital LLC (EcoR1) is an independent registered investment advisor and hedge fund manager headquartered in San Francisco, California. The firm was founded by Oleg Nodelman in 2012. EcoR1 serves as the general partner of and investment adviser to investment funds and provides investment advice to separate account clients. | Finance |
Panacea Acquisition Corp.
Panacea Acquisition Corp. Financial ConglomeratesFinance Panacea Acquisition Corp. is a blank check company with the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. The company was founded in April 2020 and is headquartered in San Francisco, CA. | Finance |
Neogene Therapeutics, Inc.
Neogene Therapeutics, Inc. BiotechnologyHealth Technology Neogene Therapeutics, Inc. engages in the provision T cell therapies to treat cancer. The company was founded by Ton N. M. Schumacher and Carsten Linnemann and is headquartered in New York, NY. | Health Technology |
Panacea Acquisition Corp. II
Panacea Acquisition Corp. II Financial ConglomeratesFinance Panacea Acquisition Corp. II operates as a blank check company. It seeks to effect a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses. The company was founded on January 14, 2021 and is headquartered in San Francisco, CA. | Finance |
Affinia Therapeutics, Inc.
Affinia Therapeutics, Inc. BiotechnologyHealth Technology Affinia Therapeutics, Inc. is a preclinical stage company, which engages in the research and development of gene therapy. It offers Affinia Rationally-designed Therapies (ART) platform, which develops novel therapies, focusing on the key components of a gene therapy: capsids, which are the outer shells of a virus used to package the genetic code to treat a disease; promoters, which control how the cells read the genetic code that is delivered; and manufacturing approaches, which determine the quality and cost of potential medicines. The company was founded by Luk Vandenberghe, Botond Roska, and Aaron Tward in 2019 and is headquartered in Waltham, MA. | Health Technology |